51760-22-6

Usage

Uses

Used in Research and Development:
5-Bromo-1,3-dihydroxymethylbenzene is used as a valuable intermediate for various organic syntheses, particularly in the synthesis of complex organic molecules and polymers. Its unique structure with a bromine atom and two hydroxymethyl groups makes it an essential component in the development of new compounds and materials.
Used in Pharmaceutical Manufacturing:
In the pharmaceutical industry, 5-Bromo-1,3-dihydroxymethylbenzene is used as a key intermediate in the synthesis of various drugs and pharmaceutical products. Its versatility in organic synthesis allows for the creation of a wide range of medicinal compounds with potential therapeutic applications.
Used in Specialty Chemical Production:
5-Bromo-1,3-dihydroxymethylbenzene is also utilized in the production of specialty chemicals, where its unique properties and reactivity contribute to the development of novel chemical products with specific applications in various industries. Its role as an intermediate in organic synthesis is crucial for the creation of these specialty chemicals.

Upstream product

• 121-91-5 isophthalic acid 
• 51760-21-5 dimethyl 5-bromoisophthalate 
• 1374658-80-6 dimethyl 2,2′-(5-bromo-1,3-phenylene)diacetate 
• 556-96-7 5-bromo-1,3-xylene 
• 99-27-4 dimethyl 5-aminoisophthalate 
• 23351-91-9 5-bromoisophthalic acid 
• 51760-23-7 1-bromo-3,5-bis(bromomethyl)benzene 

Downstream Products

• 120173-41-3 5-bromobenzene-1,3-dicarbaldehyde 
• 636984-39-9 C₂₈H₂₅BrO₁₀ 
• 148494-45-5 1,3-bis(5,5-dimethyl-1,3-dioxan-2-yl)-5-bromobenzene 
• 148494-46-6 3,5-bis(5,5-dimethyl-1,3-dioxan-2-yl)benzaldehyde 

Relevant academic research and scientific papers

Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens

Pentamidine, an FDA-approved antiparasitic drug, was recently identified as an outer membrane disrupting synergist that potentiates erythromycin, rifampicin, and novobiocin against Gram-negative bacteria. The same study also described a preliminary structure-activity relationship using commercially available pentamidine analogues. We here report the design, synthesis, and evaluation of a broader panel of bis-amidines inspired by pentamidine. The present study both validates the previously observed synergistic activity reported for pentamidine, while further assessing the capacity for structurally similar bis-amidines to also potentiate Gram-positive specific antibiotics against Gram-negative pathogens. Among the bis-amidines prepared, a number of them were found to exhibit synergistic activity greater than pentamidine. These synergists were shown to effectively potentiate the activity of Gram-positive specific antibiotics against multiple Gram-negative pathogens such as Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Escherichia coli, including polymyxin- and carbapenem-resistant strains.

General and Facile Route to Isomerically Pure Tricyclic Peptides Based on Templated Tandem CLIPS/CuAAC Cyclizations

We report a one-pot ligation/cyclization technology for the rapid and clean conversion of linear peptides into tricyclic peptides that is based on using tetravalent scaffolds containing two benzyl bromide and two alkyne moieties. These react via CLIPS/CuAAC reactions with cysteines and azides in the peptide. Flexibility in the scaffolds is key to the formation of isomerically pure products as the flexible scaffolds T41 and T42 mostly promote the formation of single isomeric tricycles while the rigid scaffolds T43 and T44 do not yield clean products. There seems to be no limitation to the number and types of amino acids present as 18 canonical amino acids were successfully implemented. We also observed that azides at the peptide termini and cysteine residues in the center gave better results than compounds with the functional groups placed the other way round.

MULTICYCLIC PEPTIDES AND METHODS FOR THEIR PREPARATION

The invention relates to methods for preparing a compound comprising a peptide attached to a molecular scaffold whereby multiple peptide loops are formed, to compounds that can be obtained with such methods and uses thereof.

ENDOSOMOLYTIC AGENTS FOR GENE THERAPY

Compounds of formula (I), wherein Ar is an aryl group optionally further substituted with one or more groups R3; A is a lipophilic, hydrophobic moiety; R1 is a phosphodiester, phosphotriester, thioether or amide group; X is an unsubs

ZINC COMPLEX

A zinc complex characterized in exhibiting an octahedral structure and being configured from repeating units represented by general formula (I): wherein L represents a linker region, and R1 represents a C1-4 alkyl group, which can have a halogen atom.

AROMATIC RING-CONTAINING COMPOUND AND CANCER PREVENTIVE AND/OR THERAPEUTIC AGENT

PROBLEM TO BE SOLVED: To provide cancer preventive/therapeutic means that can exhibit cancer cell-specific therapeutic effect on many cancers. SOLUTION: According to one embodiment of the present invention, an aromatic ring-containing compound represented

Structure-guided design of selective inhibitors of neuronal nitric oxide synthase

Nitric oxide synthases (NOSs) comprise three closely related isoforms that catalyze the oxidation of l-arginine to l-citrulline and the important second messenger nitric oxide (NO). Pharmacological selective inhibition of neuronal NOS (nNOS) has the potential to be therapeutically beneficial in various neurodegenerative diseases. Here, we present a structure-guided, selective nNOS inhibitor design based on the crystal structure of lead compound 1 in nNOS. The best inhibitor, 7, exhibited low nanomolar inhibitory potency and good isoform selectivities (nNOS over eNOS and iNOS are 472-fold and 239-fold, respectively). Consistent with the good selectivity, 7 binds to nNOS and eNOS with different binding modes. The distinctly different binding modes of 7, driven by the critical residue Asp597 in nNOS, offers compelling insight to explain its isozyme selectivity, which should guide future drug design programs.

Construction of hexanuclear macrocycles by a coupling strategy from polyfunctionalized bis(terpyridines)

The construction of a heteronuclear (Ru4Fe2) hexameric metallomacrocycle with methyl- and carbonyl-functionalized bis(terpyridyl) moieties was achieved by a self-assembly of a dinuclear trimer, which was prepared in high yield via Pd

Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use

The present invention is related to new tomaymycin derivatives having a linking chain between two units of pyrrolo[2,1c][1,4]benzodiazepines, substituted by a non-cleavable linker and their conjugated to cell binding agents, their process of preparation a

ALYKYLENE DERIVATIVE HAVING EDG RECEPTOR ANTAGONISM

PROBLEM TO BE SOLVED: To provide novel compounds having EDG (endothelial differentiation gene) receptor antagonism which are useful as active components of drugs for preventing and/or treating inflammatory diseases or the like. SOLUTION: The compounds are represented by formula (I) (wherein R1 is hydrogen or an alkyl group; R2 is hydrogen present at any substitutable position on ring C or a substituent such as a hydroxy group, a carboxy group, and a nitro group; R3 is hydrogen present at any substitutable position on ring D or a substitutent such as a hydroxy group and an aralkyloxy group; X is an alkylamino group, an amino group or the like; Y is a carboxy group, a sulfo group or a phosphono group; Z is oxygen, sulfur or the like; a ring represented by A is a 5- or 6-membered saturated or unsaturated hydrocarbon ring; and a ring represented by B is a 4- or 7-membered saturated or unsaturated hydrocarbon ring containing one -C=C- as a partial structure shown in the above formula) and include their salts and their esters.